Emergex Vaccines, a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, announced it has built its Finance team and strengthening its operational capabilities.
Alex Bronimann joins Emergex as Finance Director. He brings more than 20 years’ experience in the healthcare, pharmaceutical, technology, telecoms and manufacturing sectors.
Bronimann’s strengths will contribute to financial strategy, focusing on financing activities, global costing, pricing and oversight of the company’s finances. He leads day-to-day responsibility for financial controls and reporting, budgeting, forecasting, audit, tax, cash and treasury management.
Prior to Emergex, Bronimann was Finance Director at OrganOx, an Oxford University spin-out and start-up medical device company. Previously, Bronimann was Group CFO and Board Director at Adestra Group and before that he worked for several ‘blue chip’ companies including Vodafone, GE, Dell, Amersham and Cable & Wireless. Bronimann is a qualified Chartered Accountant.
Natalie Sands also joins Emergex’s new Finance function as Financial Controller. She is responsible for day-to-day financial operations including management reporting, payroll, supporting the audit process, and establishing robust financial policies and procedures.
Sands has a broad range of experience in commercial finance including at large companies such as Live Nation Entertainment and Amey. She joins Emergex from Amey, where she was Senior Accountant within the Investments division, which included complex accounting for Special Purpose Vehicle Companies (SPV).
Prior to this she was Group Financial Controller for Summit Therapeutics. Sands is a qualified Chartered Certified Accountant and is a Fellow member of the Association of Chartered Certified Accountants.
Professor Thomas Rademacher, cofounder, CEO and CSO at Emergex commented: “Alex and Natalie join Emergex at an exciting time in our growth as we look to advance the development of EMX-001, our universal Flavivirus vaccine candidate, for diseases such as Zika, Dengue and Yellow Fever towards clinical development early next year and our universal Filovirus and Influenza programmes in preclinical development."
"The new capabilities that Alex and Natalie bring will help support fundraising and ensure that we establish strong financial governance and cost controls as we grow.”
